ReviewBone marrow transplantation2008
Stem cell transplantation for neuroblastoma.
Review in Bone marrow transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.Targeted oncology · 2024Pooled it
- A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.Bone marrow transplantation · 2013Trial
- Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- Predictors of non-compliance in autologous hematopoietic SCT patients undergoing out-patient transplants.Bone marrow transplantation · 2012Trial
- Impact ofEuropean journal of pediatrics · 2026Article
- Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma.The Cochrane database of systematic reviews · 2025Article
- Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.Molecular neurobiology · 2025Review
- Pediatric central nervous system (CNS) neuroblastoma: A case report.Surgical neurology international · 2024Article
- Article
- Development and validation of a predictive model to guide the use of plerixafor in pediatric population.Bone marrow transplantation · 2022Article
- MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.Cancers · 2022Review
- Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review.Cancers · 2022Review
- A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key.Frontiers in pediatrics · 2021Review
- Cancer stem cells in neuroblastoma therapy resistance.Cancer drug resistance (Alhambra, Calif.) · 2019Article
- Engineered human mesenchymal stem cells for neuroblastoma therapeutics.Oncology reports · 2019Article
- Surgical removal of adult recurrent neuroblastoma located in the posterior mediastinum and retroperitoneum: A case report.Medicine · 2018Article
- Morus alba Accumulates Reactive Oxygen Species to Initiate Apoptosis via FOXO-Caspase 3-Dependent Pathway in Neuroblastoma Cells.Molecules and cells · 2015Article
- Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.Bone marrow transplantation · 2013Article
- Neuroblastoma: issues in transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
High-risk neuroblastoma is a childhood malignancy with a poor prognosis. Gradual improvements in survival have correlated with therapeutic intensity, and the ability to harvest, process and store autologous hematopoietic stem cells has allowed for dose intensification beyond marrow tolerance. The use of high-dose chemotherapy with autologous hematopoietic stem cell rescue in consolidation has resulted in improvements in survival, although further advances are still needed. Newer approaches to SCT and supportive care, most notably the transition to PBSC, have resulted in further improvement in survival and decreases in treatment-related mortality. Research into experimental approaches to hematopoietic SCT is ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.